SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
青山见秋
Lv4
420 积分
2022-06-06 加入
最近求助
最近应助
互助留言
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
1个月前
已关闭
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
1个月前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
1个月前
已完结
Hepatocellular carcinoma in non-alcohol fatty liver disease – changing trends and specific challenges
1个月前
已完结
Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study
1个月前
已完结
Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis
1个月前
已完结
Hepatocellular Carcinoma
1个月前
已完结
Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience
2个月前
已完结
A Liver Stiffness-Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma
2个月前
已完结
Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
2个月前
已完结
没有进行任何应助
暂时不需要【积分已退回】
1个月前
感谢
1个月前
感谢
1个月前
感谢
1个月前
感谢
1个月前
感谢
2个月前
感谢
2个月前
求正式发布版本,谢谢
3个月前
感谢
3个月前
感谢
3个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论